Katarzyna Krzywicka1, Anita van de Munckhof1, Mayte Sánchez van Kammen1, Mirjam R Heldner1, Katarina Jood1, Erik Lindgren1, Turgut Tatlisumak1, Jukka Putaala1, Johanna A Kremer Hovinga1, Saskia Middeldorp1, Marcel M Levi1, Charlotte Cordonnier1, Marcel Arnold1, Aeilko H Zwinderman1, José M Ferro1, Jonathan M Coutinho1, Diana Aguiar de Sousa2. 1. From the Departments of Neurology (K.K., A.v.d.M., M.S.v.K., J.M.C.) and Vascular Medicine (M.M.L.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; Departments of Neurology (M.R.H., M.A.) and Hematology (J.A.K.H.), Inselspital, Bern University Hospital, University of Bern; Department of Neurology (K.J., E.L., T.T.), Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J., E.L., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Neurology (J.P.), Helsinki University Hospital and University of Helsinki, Finland; Department of Internal Medicine (S.M.) and Radboud Institute of Health Sciences (S.M.), Radboud University Medical Center, Nijmegen, the Netherlands; National Institute for Health Research University College London Hospitals Biomedical Research Centre (M.M.L.), UK; University of Lille (C.C.), Inserm, CHU Lille, U1172-Lille Neuroscience and Cognition, France; Department of Clinical Epidemiology and Biostatistics (A.H.Z.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; and Department of Neurosciences and Mental Health (J.M.F., D.A.d.S.), Neurology Service, Hospital de Santa Maria/Centro Hospitalar Universitário Lisboa Norte (CHULN), University of Lisbon, Portugal. 2. From the Departments of Neurology (K.K., A.v.d.M., M.S.v.K., J.M.C.) and Vascular Medicine (M.M.L.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; Departments of Neurology (M.R.H., M.A.) and Hematology (J.A.K.H.), Inselspital, Bern University Hospital, University of Bern; Department of Neurology (K.J., E.L., T.T.), Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J., E.L., T.T.), Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden; Department of Neurology (J.P.), Helsinki University Hospital and University of Helsinki, Finland; Department of Internal Medicine (S.M.) and Radboud Institute of Health Sciences (S.M.), Radboud University Medical Center, Nijmegen, the Netherlands; National Institute for Health Research University College London Hospitals Biomedical Research Centre (M.M.L.), UK; University of Lille (C.C.), Inserm, CHU Lille, U1172-Lille Neuroscience and Cognition, France; Department of Clinical Epidemiology and Biostatistics (A.H.Z.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands; and Department of Neurosciences and Mental Health (J.M.F., D.A.d.S.), Neurology Service, Hospital de Santa Maria/Centro Hospitalar Universitário Lisboa Norte (CHULN), University of Lisbon, Portugal. dianasousa@campus.ul.pt.
Abstract
BACKGROUND AND OBJECTIVES: Cerebral venous sinus thrombosis (CVST) as a part of the thrombosis and thrombocytopenia syndrome is a rare adverse drug reaction of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) vaccination. Estimated background rate of CVST with thrombocytopenia is 0.1 per million per month. We assessed the age-stratified risk of CVST with and without thrombocytopenia after SARS-CoV-2 vaccination. METHODS: We estimated the absolute risk of CVST with and without thrombocytopenia within 28 days of a first dose of 4 SARS-CoV-2 vaccinations using data from the European Medicines Agency's EudraVigilance database (until June 13, 2021). As a denominator, we used data on vaccine delivery from 31 European countries. For 22.8 million adults from 25 countries, we estimated the absolute risk of CVST after the first dose of ChAdOx1 nCov-19 per age category. RESULTS: The absolute risk of CVST within 28 days of first-dose vaccination was 7.5 (95% confidence interval [CI] 6.9-8.3), 0.7 (95% CI 0.2-2.4), 0.6 (95% CI 0.5-0.7), and 0.6 (95% CI 0.3-1.1) per million of first doses of ChAdOx1 nCov-19, Ad26.COV2.S, BNT162b2, and mRNA-1273, respectively. The absolute risk of CVST with thrombocytopenia within 28 days of first dose vaccination was 4.4 (95% CI 3.9-4.9), 0.7 (95% CI 0.2-2.4), 0.0 (95% CI 0.0-0.1), and 0.0 (95% CI 0.0-0.2) per million of first doses of ChAdOx1 nCov-19, Ad26.COV2.S, BNT162b2, and mRNA-1273, respectively. In recipients of ChAdOx1 nCov-19, the absolute risk of CVST, both with and without thrombocytopenia, was the highest in the 18- to 24-year-old group (7.3 per million, 95% CI 2.8-18.8 and 3.7 per million, 95% CI 1.0-13.3, respectively). The risk of CVST with thrombocytopenia in ChAdOx1 nCov-19 recipients was the lowest in the age group ≥70 years (0.2, 95% CI 0.0-1.3). Age <60 years compared to ≥60 years was a predictor for CVST with thrombocytopenia (incidence rate ratio 5.79, 95% CI 2.98-11.24, p < 0.001). DISCUSSION: The risk of CVST with thrombocytopenia within 28 days of first-dose vaccination with ChAdOx1 nCov-19 was higher in younger age groups. The risk of CVST with thrombocytopenia was slightly increased in patients receiving Ad26.COV2.S compared with the estimated background risk. The risk of CVST with thrombocytopenia was not increased in recipients of SARS-CoV-2 mRNA vaccines.
BACKGROUND AND OBJECTIVES: Cerebral venous sinus thrombosis (CVST) as a part of the thrombosis and thrombocytopenia syndrome is a rare adverse drug reaction of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) vaccination. Estimated background rate of CVST with thrombocytopenia is 0.1 per million per month. We assessed the age-stratified risk of CVST with and without thrombocytopenia after SARS-CoV-2 vaccination. METHODS: We estimated the absolute risk of CVST with and without thrombocytopenia within 28 days of a first dose of 4 SARS-CoV-2 vaccinations using data from the European Medicines Agency's EudraVigilance database (until June 13, 2021). As a denominator, we used data on vaccine delivery from 31 European countries. For 22.8 million adults from 25 countries, we estimated the absolute risk of CVST after the first dose of ChAdOx1 nCov-19 per age category. RESULTS: The absolute risk of CVST within 28 days of first-dose vaccination was 7.5 (95% confidence interval [CI] 6.9-8.3), 0.7 (95% CI 0.2-2.4), 0.6 (95% CI 0.5-0.7), and 0.6 (95% CI 0.3-1.1) per million of first doses of ChAdOx1 nCov-19, Ad26.COV2.S, BNT162b2, and mRNA-1273, respectively. The absolute risk of CVST with thrombocytopenia within 28 days of first dose vaccination was 4.4 (95% CI 3.9-4.9), 0.7 (95% CI 0.2-2.4), 0.0 (95% CI 0.0-0.1), and 0.0 (95% CI 0.0-0.2) per million of first doses of ChAdOx1 nCov-19, Ad26.COV2.S, BNT162b2, and mRNA-1273, respectively. In recipients of ChAdOx1 nCov-19, the absolute risk of CVST, both with and without thrombocytopenia, was the highest in the 18- to 24-year-old group (7.3 per million, 95% CI 2.8-18.8 and 3.7 per million, 95% CI 1.0-13.3, respectively). The risk of CVST with thrombocytopenia in ChAdOx1 nCov-19 recipients was the lowest in the age group ≥70 years (0.2, 95% CI 0.0-1.3). Age <60 years compared to ≥60 years was a predictor for CVST with thrombocytopenia (incidence rate ratio 5.79, 95% CI 2.98-11.24, p < 0.001). DISCUSSION: The risk of CVST with thrombocytopenia within 28 days of first-dose vaccination with ChAdOx1 nCov-19 was higher in younger age groups. The risk of CVST with thrombocytopenia was slightly increased in patients receiving Ad26.COV2.S compared with the estimated background risk. The risk of CVST with thrombocytopenia was not increased in recipients of SARS-CoV-2 mRNA vaccines.
Authors: Philipp Fervers; Jonathan Kottlors; Thorsten Persigehl; Simon Lennartz; Volker Maus; Sebastian Fischer; Hanna Styczen; Cornelius Deuschl; Marc Schlamann; Anastasios Mpotsaris; Seraphine Zubel; Michael Schroeter; David Maintz; Gereon Rudolf Fink; Nuran Abdullayev Journal: J Clin Neurosci Date: 2022-06-06 Impact factor: 2.116
Authors: Katarzyna Krzywicka; Anita van de Munckhof; Julian Zimmermann; Felix J Bode; Giovanni Frisullo; Theodoros Karapanayiotides; Bernd Pötzsch; Mayte Sánchez van Kammen; Mirjam R Heldner; Marcel Arnold; Johanna A Kremer Hovinga; José M Ferro; Diana Aguiar de Sousa; Jonathan M Coutinho Journal: Blood Date: 2022-04-28 Impact factor: 25.476
Authors: Adrian Scutelnic; Katarzyna Krzywicka; Sven Poli; Mirjam R Heldner; Joshua Mbroh; Anita van de Munckhof; Mayte Sánchez van Kammen; Diana Aguiar de Sousa; Erik Lindgren; Katarina Jood; Albrecht Günther; Sini Hiltunen; Jukka Putaala; Andreas Tiede; Frank Maier; Rolf Kern; Thorsten Bartsch; Katharina Althaus; Alfonso Ciccone; Markus Wiedmann; Mona Skjelland; Antonio Medina; Elisa Cuadrado-Godia; Thomas Cox; Avinash Aujayeb; Nicolas Raposo; Katia Garambois; Jean-Francois Payen; Fabrice Vuillier; Guillaume Franchineau; Serge Timsit; David Bougon; Marie-Cécile Dubois; Audrey Tawa; Clement Tracol; Emmanuel De Maistre; Fabrice Bonneville; Caroline Vayne; Annerose Mengel; Dominik Michalski; Johann Pelz; Matthias Wittstock; Felix Bode; Julian Zimmermann; Judith Schouten; Alina Buture; Sean Murphy; Vincenzo Palma; Alberto Negro; Alexander Gutschalk; Simon Nagel; Silvia Schoenenberger; Giovanni Frisullo; Carla Zanferrari; Francesco Grillo; Fabrizio Giammello; Mar Morin Martin; Alvaro Cervera; Jim Burrow; Carlos Garcia Esperon; Beng Lim Alvin Chew; Timothy J Kleinig; Cristina Soriano; Domenico S Zimatore; Marco Petruzzellis; Ahmed Elkady; Miguel S Miranda; João Fernandes; Åslög Hellström Vogel; Elias Johansson; Anemon Puthuppallil Philip; Shelagh B Coutts; Simerpreet Bal; Brian Buck; Catherine Legault; Dylan Blacquiere; Hans D Katzberg; Thalia S Field; Vanessa Dizonno; Thomas Gattringer; Christian Jacobi; Annemie Devroye; Robin Lemmens; Espen Saxhaug Kristoffersen; Monica Bandettini di Poggio; Masoud Ghiasian; Theodoros Karapanayiotides; Sophie Chatterton; Miriam Wronski; Karl Ng; Robert Kahnis; Thomas Geeraerts; Peggy Reiner; Charlotte Cordonnier; Saskia Middeldorp; Marcel Levi; Eric C M van Gorp; Diederik van de Beek; Justine Brodard; Johanna A Kremer Hovinga; Marieke J H A Kruip; Turgut Tatlisumak; José M Ferro; Jonathan M Coutinho; Marcel Arnold Journal: Ann Neurol Date: 2022-07-04 Impact factor: 11.274
Authors: Anita van de Munckhof; Erik Lindgren; Timothy J Kleinig; Thalia S Field; Charlotte Cordonnier; Katarzyna Krzywicka; Sven Poli; Mayte Sánchez van Kammen; Afshin Borhani-Haghighi; Robin Lemmens; Adrian Scutelnic; Alfonso Ciccone; Thomas Gattringer; Matthias Wittstock; Vanessa Dizonno; Annemie Devroye; Ahmed Elkady; Albrecht Günther; Alvaro Cervera; Annerose Mengel; Beng Lim Alvin Chew; Brian Buck; Carla Zanferrari; Carlos Garcia-Esperon; Christian Jacobi; Cristina Soriano; Dominik Michalski; Zohreh Zamani; Dylan Blacquiere; Elias Johansson; Elisa Cuadrado-Godia; Fabrice Vuillier; Felix J Bode; François Caparros; Frank Maier; Georgios Tsivgoulis; Hans D Katzberg; Jiangang Duan; Jim Burrow; Johann Pelz; Joshua Mbroh; Joyce Oen; Judith Schouten; Julian Zimmermann; Karl Ng; Katia Garambois; Marco Petruzzellis; Mariana Carvalho Dias; Masoud Ghiasian; Michele Romoli; Miguel Miranda; Miriam Wronski; Mona Skjelland; Mostafa Almasi-Dooghaee; Pauline Cuisenier; Seán Murphy; Serge Timsit; Shelagh B Coutts; Silvia Schönenberger; Simon Nagel; Sini Hiltunen; Sophie Chatterton; Thomas Cox; Thorsten Bartsch; Vahid Shaygannejad; Zahra Mirzaasgari; Saskia Middeldorp; Marcel M Levi; Johanna A Kremer Hovinga; Katarina Jood; Turgut Tatlisumak; Jukka Putaala; Mirjam R Heldner; Marcel Arnold; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho Journal: Stroke Date: 2022-09-09 Impact factor: 10.170